Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s share price traded down 5.9% during mid-day trading on Tuesday . The company traded as low as $2.99 and last traded at $3.01. 2,281,447 shares changed hands during mid-day trading, an increase of 12% from the average session volume of 2,038,004 shares. The stock had previously closed at $3.20.
A number of equities analysts recently issued reports on the stock. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. B. Riley assumed coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 target price for the company. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Leerink Swann restated a “buy” rating and set a $5.00 price objective on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $4.89.
The firm has a market cap of $414.95, a PE ratio of -6.14 and a beta of 1.32.
COPYRIGHT VIOLATION NOTICE: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2018/02/20/achillion-pharmaceuticals-achn-stock-price-down-5-9.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.